SLC43A2-mediated immune cell infiltration: a potential therapeutic target in acute myeloid leukemia
The SLC43A2 gene may serve as a diagnostic, prognostic, and potential immune-related biomarker for AML patients. Blocking SLC43A2-associated signaling pathways could provide novel insights into immunotherapy for AML.
Authors
- Jile Liu
- Mingfeng Zhao (ORCID: https://orcid.org/0000-0002-5995-7558)
- Mengnan Li
- Yu Zhang (ORCID: https://orcid.org/0000-0002-4870-3480)
- Bing Wang (ORCID: https://orcid.org/0000-0003-3050-4712)
- Yanyu Jiang
- Mohan Zhao
- Tao Zhang
Institutions
- Nankai University (CN)
- Tianjin First Center Hospital (CN)
- Tianjin Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-25
- DOI
- https://doi.org/10.3389/fimmu.2025.1655766
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00